KLRC1 and neoplasm: Importantly, a variety of approaches can be considered to enhance NK cell-mediated tumor immunity in preinvasive disease, including antibodies that block inhibitory receptors (NKG2A) or to prevent MICA/B proteolytic shedding by tumor cells128,129.